<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02566551</url>
  </required_header>
  <id_info>
    <org_study_id>GTM-02</org_study_id>
    <nct_id>NCT02566551</nct_id>
  </id_info>
  <brief_title>Prospective Controlled Randomized Study of PAE vs TURP for BPH Treatment.</brief_title>
  <official_title>Prospective Controlled Randomized Study of Prostatic Arteries Embolization (PAE) vs Transurethral Resection of the Prostate (TURP) for Benign Prostatic Hyperplasia (BPH) Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Group of Research in Minimally Invasive Techniques</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Clínico Universitario Lozano Blesa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad de Zaragoza</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Group of Research in Minimally Invasive Techniques</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective randomized controlled study is to compare the improvement of
      symptoms from benign prostatic hyperplasia (BPH) and the improvement of QoL, in patients
      undergoing prostatic artery embolization (PAE) or conventional transurethral resection of the
      prostate (TURP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this prospective randomized controlled study is to compare the improvement of
      symptoms from benign prostatic hyperplasia (BPH) as assessed by the International Prostate
      Symptom Score (IPSS) and the improvement of QoL assessed by QoL questionnaire in patients
      undergoing prostatic artery embolization (PAE) to patients of similar characteristics
      undergoing conventional transurethral resection of the prostate (TURP).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of symptoms</measure>
    <time_frame>12 months</time_frame>
    <description>Improvement (change) of symptoms assessed by IPSS Score (International Prostate Symptom Score )</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in QoL</measure>
    <time_frame>12 months</time_frame>
    <description>Improvement (change) of quality of life assessed by QoL score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization post procedure</measure>
    <time_frame>3 weeks</time_frame>
    <description>Number of days of postprocedure hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preservation of erectile function</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in erectile function using the International Index of Erectile Function (IIEF)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Maximum urinary flow rate</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in maximum urinary flow rate (Qmax)</description>
  </other_outcome>
  <other_outcome>
    <measure>Post-void residual urinary volume</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in post-void residual urinary volume (PVR)</description>
  </other_outcome>
  <other_outcome>
    <measure>Detrusor pressure</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in detrusor pressure (Pdet)</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean prostate volume</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in mean prostate volume, as determined by transrectal US</description>
  </other_outcome>
  <other_outcome>
    <measure>Structural and morphological changes in MRI</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in mean prostate volume, and structural and morphological changes as determined by MRI</description>
  </other_outcome>
  <other_outcome>
    <measure>Prostate specific antigen</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in prostate specific antigen (PSA)</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Overall adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>Procedure related adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Procedure related adverse events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Prostate artery embolization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prostatic artery embolization (PAE) To perform embolization, gelatin microspheres (300-500 microns) will be used in this arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transurethral resection of the prostate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transurethral resection of the prostate (TURP) A bipolar electrosurgery generator will be used to perform TURP</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PAE</intervention_name>
    <description>Embolization of the prostate with gelatin embolization spheres via microcatheterization of the prostatic arteries.</description>
    <arm_group_label>Prostate artery embolization</arm_group_label>
    <other_name>Prostate artery embolization</other_name>
    <other_name>Prostate arteries embolization</other_name>
    <other_name>Embolization of the prostate</other_name>
    <other_name>Prostatic artery embolization</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gelatin microspheres</intervention_name>
    <description>Gelatin embolization microspheres (300-500 microns) will be used as embolic material for the prostatic artery embolization (PAE) protocol</description>
    <arm_group_label>Prostate artery embolization</arm_group_label>
    <other_name>Embolization microspheres</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TURP</intervention_name>
    <description>Bipolar transurethral resection of the prostate</description>
    <arm_group_label>Transurethral resection of the prostate</arm_group_label>
    <other_name>Transurethral resection of the prostate</other_name>
    <other_name>Transurethral prostatic resection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bipolar electrosurgery generator</intervention_name>
    <description>A bipolar electrosurgery generator will be used to perform transurethral resection of the prostate (TURP)</description>
    <arm_group_label>Transurethral resection of the prostate</arm_group_label>
    <other_name>Transurethral prostatic resection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients evaluated in the Urology Service because of BPH, candidate to TURP.

          -  Signed informed consent

          -  Lower urinary tract symptoms (LUTS) secondary to BPH for at least 6 months prior to
             study AND/OR baseline IPSS Score &gt; 13 AND/OR acute urinary retention with
             impossibility to remove urinary catheter AND/OR BPH symptoms refractory to medical
             treatment or for whom medication is contraindicated, not tolerated or refused Prostate
             size of at least 50 grams measured by MRI

          -  Patient must meet ONE of the following criteria:

               1. Baseline Prostate Specific Antigen (PSA) &lt;4 ng/mL (no prostate biopsy required)

               2. Baseline PSA &gt;4 ng/mL and ≤10 ng/mL AND free PSA &gt; 15% of total PSA (no prostate
                  biopsy required)

               3. Baseline PSA &gt;4 ng/mL and ≤10 ng/mL AND free PSA &lt;15% of total PSA AND a negative
                  prostate biopsy result (minimum 12 core biopsy)

               4. Baseline PSA &gt;10 ng/mL AND a negative prostate biopsy (minimum 12 core biopsy)

        Exclusion Criteria:

          -  Active urinary tract infection

          -  Patients with cystoscopy findings suspicious for bladder cancer must undergo biopsy
             and have a negative histopathology report to be enrolled in the study

          -  Biopsy proven prostate or bladder cancer

          -  The following patients must undergo prostate biopsy with a minimum of 12 cores and
             have a negative histopathology report to be enrolled in the study:

               -  Patients with digital rectal examination (DRE) findings suspicious for prostate
                  cancer

               -  Patients with baseline PSA levels &gt; 10 ng/mL

               -  Patients with baseline PSA levels &gt;4 ng/mL and &lt; 10 ng/mL AND free PSA &lt; 15% of
                  total PSA

          -  Bladder atonia, neurogenic bladder disorder or other neurological disorder that is
             impacting bladder function (eg multiple sclerosis, Parkinson's disease, spinal cord
             injuries, etc)

          -  Urethral stricture, bladder neck contracture, sphincter abnormalities, urinary
             obstruction due to causes other than BPH, or other potentially confounding bladder or
             urethral disease or condition

          -  Allergy to iodinated contrast agents

          -  Hypersensitivity to gelatin products

          -  Previous non-medical BPH treatment, including surgery, TURP, needle ablation,
             microwave or laser therapy, balloon dilation, stent implantation, or any other
             invasive treatment to the prostate

          -  Known major iliac arterial occlusive disease or any known condition that
             catheterization of the prostatic arteries or is a contraindication to embolization, as
             vasospasm, anatomical variations that imply a risk of embolization, bleeding,
             prostatic arteries diameter inferior to microcatheter profile, pelvic inflammatory
             disease

          -  Contraindication to magnetic resonance imaging

          -  History of prostatitis in the last 5 years, not totally controlled with medical
             treatment

          -  History of pelvic irradiation or radical pelvic surgery

          -  Coagulation disturbances not normalized by medical treatment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel A De Gregorio, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zaragoza. Chairman of Radiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alicia Laborda, PhD</last_name>
    <phone>0034976761549</phone>
    <email>alaborda@unizar.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miguel A De Gregorio, PhD</last_name>
    <phone>0034629817535</phone>
    <email>mgregori@unizar.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Sanchez-Ballestin, MD</last_name>
      <phone>677840146</phone>
      <email>mirisanba@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Miguel A De gregorio, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Sanchez-Ballestin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2015</study_first_submitted>
  <study_first_submitted_qc>October 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2015</study_first_posted>
  <last_update_submitted>August 2, 2017</last_update_submitted>
  <last_update_submitted_qc>August 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Group of Research in Minimally Invasive Techniques</investigator_affiliation>
    <investigator_full_name>José A. Guirola, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Prostatic artery embolization</keyword>
  <keyword>Transurethral resection of the prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

